CordenPharma is set to make a historic investment of approximately €900 million over the next three years to bolster its peptide platform in both the U.S., specifically in Colorado, and Europe. These initiatives will involve expanding existing facilities and constructing new ones to meet the highest quality and technical standards required for short and long peptide manufacturing, including complying with stringent Biologics License Applications (BLA) requirements. The company aims to solidify its position as a market leader in providing a wide range of services, from APIs to Drug Products, for both Injectable and Oral Peptides.
The expansion in Colorado will focus on increasing large-scale peptide manufacturing capacity to cater to the rising demand for GLP-1 peptides, driven by long-term manufacturing contracts amounting to around €3 billion. On the other hand, the European expansion will see the construction of a new state-of-the-art greenfield facility dedicated to small to large-scale peptide development and manufacturing. These expansion plans are part of CordenPharma’s strategy to achieve a sales target of €1 billion for its Peptide Platform by 2028 and further establish itself as a top-tier CDMO for various modalities, including Peptides.
CordenPharma’s ambitious growth plans have been supported by Astorg, a prominent private equity firm that acquired the company in 2022. The investments in expanding its peptide platform are geared towards strengthening the company’s ability to support innovators in developing transformative medicines. By leveraging its expertise in peptide manufacturing, CordenPharma aims to play a significant role in advancing the pharmaceutical industry and enhancing its position as a trusted outsourcing partner for companies across the drug development lifecycle.
